Progress, Potential, and Possibilities Podcast / Show · Ira Pastor

The Future of Psychedelic Medicine | Interview with Compass Pathways CEO Kabir Nath

March 9, 2026·38 min·2 clips

Kabir Nath shares how his father's suicide drives his mission to transform mental health treatment with psychedelics.

Compass Pathways sits at the center here. The host introduces Kabir Nath as the company's Chief Executive Officer and points to his background in biopharmaceuticals, medical devices, and senior pharmaceutical leadership. The topic is serious mental health. Nath describes Compass Pathways as a biotechnology company working on evidence based psychedelic innovations, separate from casual or take home use. The delivery model gets most of the attention. The host draws a clear line between Comp360 and a daily medication someone might pick up at CVS. Nath describes a 25 milligram synthetic psilocybin dose that can produce roughly a six-hour subjective experience for many people. That session belongs in a clinic. Preparation is part of the treatment process. Before dosing, patients need to understand what may happen, what they might feel, and who will be in the room. Supervision is part of safety too. Nath says psilocybin can create an inner directed experience where people work through thoughts and memories. The monitor is there for safety, not to steer therapy. He separates safety monitoring from direct therapeutic intervention, so the session is not managed therapy in the usual sense. The subjective experience stays central. Biological and physical mechanisms may matter, but Nath presents the inner experience as part of how change can happen. The host keeps the conversation practical, moving from company background to mechanism, clinical setting, dose, preparation, and the boundaries of psychedelic medicine. The close returns to patients with serious mental health conditions.

As heard by us

A clear look at how Compass Pathways is shaping psilocybin for the clinic.

The episode follows Kabir Nath and Ira Pastner as they explain how Compass Pathways is trying to bring COMP360, its synthetic proprietary psilocybin formulation, into serious mental health care.

Read the full review in PlayNext →

Why you'd press play

If you want a plain-English map of clinic-based psychedelic treatment, start here.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Progress, Potential, and Possibilities Podcast / Show